Stephens Issues Pessimistic Forecast for Health Catalyst (NASDAQ:HCAT) Stock Price

Health Catalyst (NASDAQ:HCAT) had its target price lowered by equities research analysts at Stephens from $3.50 to $2.00 in a report released on Friday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Stephens’ target price suggests a potential upside of 51.52% from the company’s previous close.

Other research analysts also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Health Catalyst in a research note on Monday, December 29th. Stifel Nicolaus decreased their target price on shares of Health Catalyst from $3.75 to $2.00 and set a “hold” rating on the stock in a research report on Friday. Canaccord Genuity Group lowered their target price on shares of Health Catalyst from $5.00 to $2.00 and set a “buy” rating for the company in a report on Friday. Raymond James Financial set a $3.00 price target on shares of Health Catalyst in a research report on Friday. Finally, Citigroup cut their price target on shares of Health Catalyst from $3.25 to $2.75 and set a “neutral” rating on the stock in a research note on Friday, January 9th. Five analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $3.16.

Health Catalyst Price Performance

HCAT stock opened at $1.32 on Friday. The stock has a market capitalization of $93.36 million, a price-to-earnings ratio of -0.52 and a beta of 1.76. The company has a quick ratio of 1.88, a current ratio of 1.88 and a debt-to-equity ratio of 0.46. Health Catalyst has a 52-week low of $1.20 and a 52-week high of $5.06. The stock’s fifty day simple moving average is $2.05 and its 200-day simple moving average is $2.56.

Health Catalyst (NASDAQ:HCAT) last released its earnings results on Thursday, March 12th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.02). Health Catalyst had a negative net margin of 57.20% and a negative return on equity of 3.98%. The business had revenue of $74.68 million during the quarter, compared to analyst estimates of $73.99 million. Equities research analysts expect that Health Catalyst will post -0.33 EPS for the current year.

Institutional Trading of Health Catalyst

Hedge funds and other institutional investors have recently modified their holdings of the business. Invesco Ltd. increased its position in shares of Health Catalyst by 6.5% during the fourth quarter. Invesco Ltd. now owns 118,591 shares of the company’s stock worth $283,000 after acquiring an additional 7,186 shares during the last quarter. Strong Retirement Solutions LLC purchased a new position in Health Catalyst in the fourth quarter valued at about $89,000. nVerses Capital LLC acquired a new stake in Health Catalyst during the 4th quarter valued at approximately $25,000. Quadrature Capital Ltd acquired a new stake in Health Catalyst during the 4th quarter valued at approximately $64,000. Finally, Bridgeway Capital Management LLC increased its holdings in Health Catalyst by 36.4% during the 4th quarter. Bridgeway Capital Management LLC now owns 129,600 shares of the company’s stock worth $310,000 after purchasing an additional 34,600 shares during the last quarter. 85.00% of the stock is owned by hedge funds and other institutional investors.

Health Catalyst News Roundup

Here are the key news stories impacting Health Catalyst this week:

• Positive Sentiment: Revenue and some profitability metrics showed resilience: Q4 revenue slightly beat consensus ($74.68M vs. $73.99M) and the company reported full‑year revenue of $311.1M with Adjusted EBITDA of $41.4M — signals that core demand remains. Health Catalyst Reports Fourth Quarter and Year End 2025 Results
• Positive Sentiment: Some chart/analyst commentary suggests the stock may be finding technical support (hammer pattern) and that earnings‑estimate revisions could stabilize — a possible near‑term bottom for opportunistic buyers. HCAT May Find a Bottom Soon
• Neutral Sentiment: Management has launched a strategic review and the CEO would not rule out a potential sale — this could unlock value but also creates uncertainty around capital allocation and timing. Seeking Alpha: CEO declines to rule out sale
• Negative Sentiment: The quarter showed an EPS miss and continued negative margins — Q4 EPS missed estimates (reported ~$0.08 vs. consensus around $0.10), which undercut confidence in near‑term profitability. MarketBeat Q4 results summary
• Negative Sentiment: Q1 revenue guidance was lowered to $68.0M–$70.0M vs. consensus ~ $74.1M — the guidance shortfall appears to be the main driver of the selloff since it signals softer near‑term top‑line momentum. Earnings press release / guidance
• Negative Sentiment: Multiple sell‑side firms lowered price targets and moved to neutral/hold/equal‑weight (Citigroup to $1.75, Stephens and Stifel to $2.00), increasing downward pressure and reducing buy‑side conviction. Analyst price-target cuts (Benzinga)
• Negative Sentiment: Market reaction was amplified by heavy volume and headlines emphasizing the mixed print and management uncertainty, leading to sharp intraday selling despite the revenue beat. MSN: stock reaction

Health Catalyst Company Profile

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.